This Viewpoint discusses regulatory shifts and their effects on access to innovative diagnostic tests and provides ways to address regulatory barriers for clinical metagenomic testing.
No takes yet. Share an insight, caveat, or question.
Chiu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: